Denis Odinokov, MBBS, MSc, PMP’s Post

Deuterium depletion is the key to getting a breakthrough in cancer therapy. Two review papers consolidate 30 years of research https://lnkd.in/dFsH-hxe #biotech #oncology

The high unmet medical need for early onset cancer has implications for the regulatory pathway and the perceived value of newly developed agents. Learn the nuanced considerations for developing and marketing a new treatment for cancer in younger adults in our upcoming webinar: https://ow.ly/hOzq50Qk9Er #earlyonsetcancer #oncology #drugdevelopment

The high unmet medical need for early onset cancer has implications for the regulatory pathway and the perceived value of newly developed agents. Learn the nuanced considerations for developing and marketing a new treatment for cancer in younger adults in our upcoming webinar: https://ow.ly/hOzq50Qk9Er #earlyonsetcancer #oncology #drugdevelopment

This is not another IL-2 story. At Aulos, we're working with AU-007, a computationally designed antibody that harnesses the power of #AI to potentially create a new cancer therapeutic. We’re encouraged by new data unveiled at SITC that show early evidence of anti-tumor activity in heavily pre-treated patients. Find out more about the Aulos approach here: https://lnkd.in/ejP3wDZa #biotechnews #ImmunoOncology #Oncology  

WATCH: Expert oncologists reflect on the evolving treatment paradigm for KRAS-mutated mNSCLC w/ insight into data from #ESMO23, discussing targeted therapies and future perspectives in clinical practice. #oncology https://lnkd.in/eNrw_tyq

US FDA #AcceleratedApproval for the First Approved #Engineered #CellTherapy for a Solid Tumor. Approved for advanced MAGE-A4+ #synovial #sarcoma in adults with certain HLA types who have received prior chemotherapy TCR-T are T cells #engineered ex vivo to express tumor-antigen specific T cell receptors (TCRs) that recognise HLA-presented proteins (HLA restriction of TCRs) that may be derived from any cellular compartment unlikely from #CARs that recognise natively folded proteins at the cell surface. This difference has significant implications first of all the ability of TCR-T to aggressively target tumor cells while minimise toxicity towards healthy tissue.

Targeting #HLA peptides is and stays a valid approach that can lead to therapies with clinical impact: First ever #TCR #Tcell #immunotherapy and second TCR-based therapy (after the T cell engager Kimmtrak) approved for the treatment of #synovialsarcoma! Great news for #cancer patients and for the TCR field in general. At Alithea Bio , we are profiling #HLA peptides in never seen precision and sensitivity and with our HLA-Compass, we have unprecedented knowledge of HLA peptide presentation in health and disease. #precisionmedicine #cellandgenetherapy #act

In recent years, advanced imaging technology, biomarkers, and innovative treatment strategies transformed the management of prostate cancer, allowing clinicians to identify subtypes of prostate cancer, tailor treatment plans, maximize efficacy, and minimize potential adverse effects for patients. Survival rates for prostate cancer are improving. #prostatecancer #oncology #medicalimaging

The high unmet medical need for early onset cancer has implications for the regulatory pathway and the perceived value of newly developed agents. Learn the nuanced considerations for developing and marketing a new treatment for cancer in younger adults in our upcoming webinar: https://ow.ly/hOzq50Qk9Er #earlyonsetcancer #oncology #drugdevelopment

On National Cancer Awareness Day, let’s take a pledge to raise cancer awareness, for its prevention, diagnosis, screening, and treatment. We, at Jubilant Biosys have been helping our partners across the globe for discovery, design and development of novel molecules in oncology. #Cancer #oncology #drugdiscovery #CRO #CRDMO #NCE #discoverychemistry #contractresearchorganization #IDD #yourcrdmopartner #science #oncologyresearch #cancerresearch